Volume 10, Issue 3 (Summer 2022)
Iran J Health Sci 2022, 10(3): 24-31 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Afshari M, Kheradmand M, Aarabi M, Parsaee M, Roozbeh F, Nezammahalleh A, et al . Co-morbidity of Diabetes and Tuberculosis Can Affect the Results of Treatment; A Case Control Study in Iran. Iran J Health Sci 2022; 10 (3) :24-31
URL: http://jhs.mazums.ac.ir/article-1-824-en.html
URL: http://jhs.mazums.ac.ir/article-1-824-en.html
Mahdi Afshari 
, Motahareh Kheradmand , Mohsen Aarabi , Mohammadreza Parsaee , Fatemeh Roozbeh , Asghar Nezammahalleh , Keyvan Heydari , Maryam Zakian , Mahmood Moosazadeh *
, Motahareh Kheradmand , Mohsen Aarabi , Mohammadreza Parsaee , Fatemeh Roozbeh , Asghar Nezammahalleh , Keyvan Heydari , Maryam Zakian , Mahmood Moosazadeh *
Gastrointestinal Cancer Research Center, Non -communicable Diseases Institute , mmoosazadeh1351@gmail.com
Abstract: (1001 Views)
Background and Purpose: Several evidences have shown some synergistic effect of diabetes co-morbidity on the tuberculosis (TB) treatment results, while some other studies have not found such associations. This study aimed to investigate the relationship between TB-diabetes co-morbidity and outcomes of TB treatment.
Materials and Methods: The research population in this case control study were patients with smear positive tuberculosis. The cases were 158 patients with TB and diabetes selected by consensus method, while controls were 316 patients randomly selected from TB patients without diabetes.
Results: Frequency of unfavorable outcome among cases was higher than among controls (7.6% vs 7.3% respectively, p-value =0.901). Multivariate logistic regression models showed that the odds ratios for adverse treatment outcome, death, treatment failure, positive smear after the intensive phase of treatment and high grade positivity (2+ & 3+) were 0.97(0.45- 2.06), 0.97(0.42-2.24), 0.91(0.17-4.85), 1.39(0.79- 2.44) and 2.57(0.83- 7.92) respectively. Moreover, treatment adverse outcomes among patients with drug complications (22.2% vs. 6.5%, p-value =0.010) and rural residents (10% vs 4.9% respectively, p-value =0.037) were significantly higher than those among patients without complication and urban residents respectively.
Conclusion: Although we did not observe any significant association between TB-diabetes co-morbidity and treatment results, there was a significant effect measure regarding the effect of smear positivity at the end of the intensive phase of treatment, especially high grade of smear positivity. Because of probable bias in the classification of the exposure, screening of TB patients regarding diabetes mellitus at the beginning of the treatment is recommended.
Materials and Methods: The research population in this case control study were patients with smear positive tuberculosis. The cases were 158 patients with TB and diabetes selected by consensus method, while controls were 316 patients randomly selected from TB patients without diabetes.
Results: Frequency of unfavorable outcome among cases was higher than among controls (7.6% vs 7.3% respectively, p-value =0.901). Multivariate logistic regression models showed that the odds ratios for adverse treatment outcome, death, treatment failure, positive smear after the intensive phase of treatment and high grade positivity (2+ & 3+) were 0.97(0.45- 2.06), 0.97(0.42-2.24), 0.91(0.17-4.85), 1.39(0.79- 2.44) and 2.57(0.83- 7.92) respectively. Moreover, treatment adverse outcomes among patients with drug complications (22.2% vs. 6.5%, p-value =0.010) and rural residents (10% vs 4.9% respectively, p-value =0.037) were significantly higher than those among patients without complication and urban residents respectively.
Conclusion: Although we did not observe any significant association between TB-diabetes co-morbidity and treatment results, there was a significant effect measure regarding the effect of smear positivity at the end of the intensive phase of treatment, especially high grade of smear positivity. Because of probable bias in the classification of the exposure, screening of TB patients regarding diabetes mellitus at the beginning of the treatment is recommended.
Type of Study: Original Article |
Subject:
Epidemiology
References
1. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9(12):737-46.
2. Restrepo BI, Schlesinger LS. Impact of diabetes on the natural history of tuberculosis. Diabetes Res Clin Pract. 2014;106(2):191-9.
3. Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. Eur J Immunol. 2014;44(3):617-26.
4. Kumar Nathella P, Babu S. Influence of diabetes mellitus on immunity to human tuberculosis. Immunology. 2017;152(1):13-24.
5. Shewade HD, Jeyashree K, Mahajan P, Kumar AMV. National guidelines on screening for diabetes among patients with tuberculosis in India: Need for clarity and change in screening cut off? Diabetes Metab Syndr. 2017;11 Suppl 2:S929-S30.
6. Workneh MH, Bjune GA, Yimer SA. Diabetes mellitus is associated with increased mortality duringtuberculosis treatment: a prospective cohort study among tuberculosis patients in South-Eastern Amahra Region, Ethiopia. Infect Dis Poverty. 2016;5:22.
7. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5(7):e152.
8. Alebel A, Wondemagegn AT, Tesema C, Kibret GD, Wagnew F, Petrucka P, et al. Prevalence of diabetes mellitus among tuberculosis patients in Sub-Saharan Africa: a systematic review and meta-analysis of observational studies. BMC Infect Dis. 2019;19(1):254.
9. Noubiap JJ, Nansseu JR, Nyaga UF, Nkeck JR, Endomba FT, Kaze AD, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2·3 million patients with tuberculosis. Lancet Glob Health. 2019;7(4):e448-e460.
10. Sharma D, Goel NK, Sharma MK, Walia DK, Thakare MM, Khaneja R. Prevalence of Diabetes Mellitus and its Predictors among Tuberculosis Patients Currently on Treatment. Indian J Community Med. 2018;43(4):302-306.
11. Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81.
12. KazempourDizaji M, Kazemnejad A, Tabarsi P, Zayeri F.Risk Factors Associated with Survival of Pulmonary Tuberculosis. Iran J Public Health. 2018;47(7):980-987.
13. NandakumarK V, Duraisamy K, Balakrishnan S, M S, S JS, Sagili KD, et al. Outcome of tuberculosis treatment in patients with diabetes mellitus treated in the revised national tuberculosis control programme in Malappuram District, Kerala, India. PLoS One. 2013 ;8(10):e76275.
14. Martínez-Rodríguez A, Gonzalez-Díaz A, Armas L Sanchez L, Martínez-Morales MA, González-Ochoa E. Survival of Cuban Patients with Pulmonary Tuberculosis (2009–2010). MEDICC Review, 2016; 18( 1–2):22-27.
15. Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg. 2009;80(4):634-9.
16. Jumaev G, Tillashaykhov M, Muazzamov B, Radjabov B, Gadoev J, Alikhanova N, et al. Prevalence, characteristics and treatment outcomes of all patients with new tuberculosis and diabetes mellitus in 2011–2013, Bukhara, Uzbekistan. Public health panorama, 2016;02 (01), 40 - 47.
17. Mukhtar F, Butt ZA. Risk ofadverse treatment outcomes among newpulmonary TB patients co-infected with diabetes inPakistan: A prospective cohort study. PLoS ONE. 2018; 13(11): e0207148.
18. Satung J, Kaewkungwal J, Silachamroon U, Pokaew P, Rattanajiamrangsree S, Kasetjareon Y, et al. Treatment outcomes among diabetic patients with tuberculosis in Thailand. Southeast Asian J Trop Med Public Health. 2016;47(6):1209-20.
19. Shahrezaei M, Maracy MR, Farid F. Factors affecting mortality and treatment completion of tuberculosis patients in Isfahan Province from 2006 to 2011. Int J Prev Med. 2015;6:91.
20. Al-Rifai RH, Pearson F, Critchley JA, Abu-Raddad LJ (2017) Association between diabetes mellitus and active tuberculosis: A systematic review and meta-analysis. PLoS ONE. 12(11): e0187967.
21. Perez-Navarro LM, Fuentes-Dominguez FJ, Zenteno-Cuevas R. Type 2 diabetes mellitus and its influence in the development of multidrug resistance tuberculosis in patients from southeastern Mexico. J Diabetes Complications. 2015;29(1):77-82.
22. Shariff NM, Safian N. Diabetes mellitus and its influence on sputum smear positivity at the 2nd month of treatment among pulmonary tuberculosis patients in Kuala Lumpur, Malaysia: A case control study. Int J Mycobacteriol. 2015;4(4):323-9.
23. Viswanathan V, Vigneswari A, Selvan K, Satyavani K, Rajeswari R, Kapur A. Effect of diabetes on treatment outcome of smear-positive pulmonary tuberculosis--a report from South India. J Diabetes Complications. 2014;28(2):162-5..
24. Adepoyibi T, Weigl B, Greb H, Neogi T, McGuire H. New screening technologies for type 2 diabetes mellitus appropriate for use in tuberculosis patients. Public Health Action. 2013;3(Suppl. 1):S10–17.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
